Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023003 · ClinicalTrials.gov registry record · Phase 4
Postpartum Evaluation of Nifedipine and Enalapril for Hypertension
A Phase 4 study of Hypertension in Pregnancy, sponsored by Nebraska Methodist Health System.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 850
- Enrollment target
- 1
- Study location
NCT07023003 is a Phase 4 study of Hypertension in Pregnancy that is actively recruiting participants, run by Nebraska Methodist Health System. The registered enrollment target is 850 participants, above the 383-participant average among 13 other Hypertension in Pregnancy trials with a reported enrollment target (122% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07023003, a Phase 4 study of Hypertension in Pregnancy, is actively recruiting participants, sponsored by Nebraska Methodist Health System.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 850 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine. Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study. The only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.
Conditions Studied
Interventions
- DRUG Enalapril 10mg QD
- DRUG Nifedipine 30mg XL BID
Study Locations (1)
Nebraska
- Methodist Women's Hospital - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2025-07-11 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07023003
The ClinicalTrials.gov registry entry for NCT07023003 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 383-participant average among 13 other Hypertension in Pregnancy trials with a reported enrollment target (122% higher). The listed sponsor is Nebraska Methodist Health System, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension in Pregnancy appearing as the primary indexed condition, and to 2 interventions - of which Enalapril 10mg QD is the first listed.
NCT07023003 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT07023003 about?
NCT07023003 is a clinical study titled "Postpartum Evaluation of Nifedipine and Enalapril for Hypertension". This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common b...
What is the current status of trial NCT07023003?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 850 participants. The study started on 2025-07-11. Estimated completion is 2028-12.
What conditions does trial NCT07023003 study?
This clinical trial studies the following conditions: Hypertension in Pregnancy.
What interventions are being tested in trial NCT07023003?
The interventions under investigation include: Enalapril 10mg QD (DRUG), Nifedipine 30mg XL BID (DRUG).
Who is sponsoring clinical trial NCT07023003?
This trial is sponsored by Nebraska Methodist Health System, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07023003 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension in Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
RECRUITING · Phase 4
-
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
RECRUITING · Phase 4
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Moms@Home: A Storytelling-based Mobile Health Intervention to Improve Blood Pressure Management in Pregnancy
RECRUITING · NA
-
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
RECRUITING · NA
-
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.